Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD